Small molecule progress for OncoTherapy as MELK inhibitor moves into clinic
This article was originally published in Scrip
OncoTherapy Science has initiated a clinical program for its first small molecule drug candidate, beginning enrollment in a US Phase I trial for OTS167.
You may also be interested in...
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.